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Abstract  
Introduction: Immunologic treatment failure in adult HIV patients on ART based on 
WHO treatments failure criteria which is recommended as anti-retroviral treatment 
failure diagnostic criteria especially for resource limited settings like Ethiopia where 
the gold standard viral load determination is not accessible. Patient, who start 
treatment with advanced stage in which factors lead to treatment failure is not well 
understood and well studied.     
 Objective: The aim of this study was to identify determinants of first line 
antiretroviral treatment immunologic failure among adult HIV Patients at Dessie 
Referral Hospital may, 2015 
Methods: A hospital based Unmatched case control study was conducted at Dessie 
Referral Hospital. Detailed reviews of patient record were made by using structured 
check list in which all required information have been collected. From adult HIV 
patient on antiretroviral treatment two hundred nine cases with immunological 
treatment failure were taken as a whole where as 209 controls have been selected 
in the ratio of 1:1 with computer generated simple random sampling. Data have been 
entered and cleaned using Epi Info version 7 then exported to SPSS version 20 for 
analysis. Bivariable analysis has been executed then all explanatory variables with 
p-value of <0.2 were entered into multivariable logistic regression. Determinant 
factors have been identified based on p-value and AOR with 95% CI. 
Results: In this study base line CD4 count <50 and between 50-200 cells/micro-
litter, opportunistic infections and inconsistent adherence were found to have more 
chance of developing immunologic failure where as being female and base line 
regimen ZDV+3TC+EFV were protective factors. 
Conclusion and recommendations: lower base line CD4 count, opportunistic 
infection, inconsistent adherence were found to be determinant factors to develop 
immunologic failure. Therefore clinicians and related health programs shall focus on 
the identified risk factors. 
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1. Introduction 
1.1 Statement of the problem 
Introduction of ART in sub- Saharan Africa was a hot debate due to many concerns 
about adherence, logistics and resistance even if we have a significant scale up 
implementation. The immunological approaches of WHO has considerable 
importance for this region even though it  is risk for unrecognized virologic failure 
and the subsequent development of ART-drug resistance (1).  
Expanding access to ART is changing the global HIV epidemic in momentous ways 
as a result AIDs-related mortality rates are declining rapidly. The scale up of ART 
avert an estimated 4.2 million deaths in low and middle income countries in 2002-
2012.The scale up of ART is also contributing significantly to the ongoing drop in 
annual new HIV infection around the world in all segment of population(2). 
 According to WHO 2013 Report about 21.2 million peoples are eligible for ART in 
Africa (3). In Ethiopia scale up of free ART services has been one of the greatest 
achievement of the HIV program response over the last decade. By the end of June 
2013 the number of people ever enrolled in chronic care reached 728,874 while the 
number ever started ART was 439,301 and 317,443 were currently received ART. 
Only 70.3% of individuals who ever started ART were currently on treatment 
indicating challenges in patient retention(4).     
 HIV is fully suppressed in only one in four people living in sub-Saharan Africa. 
Death rate is greater in those patients with treatment failure than those with none(5). 
So attention is needed for communities to achieve the health benefit of ART. One of 
the critical decision made in ART is when to switch from an initial regimen to another 
treatment due to treatment failure which requires consideration of multiple factors 
like what types of monitoring (clinical, immunological, virologic) in available to guide 
switching, establishing criteria for treatment failure, integrating data from different 
types of monitoring, making decision and follow up and monitoring to determine 
patient outcomes. Establishing criteria for treatment failure by considering different 
determinant factors is one of the critical clinical decisions made in antiretroviral 
therapy which helps early identification of failing regimen and  prevent drug 
resistance(6).  
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Ethiopia has now reached a symbolic mile stones for curbing the spread of the 
epidemic, where the number of newly started client on ART has suppressed the 
number of new infections in adults>15 years .Of the estimated 593,400 adults living 
with HIV at the end of 2013; 298,512 were on treatment(50%) (7). 
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1.2 literature review 
1.2.1 Immunological antiretroviral treatment failure : 
Failure of first line ART results in high morbidity and mortality. A four years cohort 
follow up study in India show that amongst 1431 PLHIV, 19.2% died,18.4 % LFU, 
of the remaining patients 62.3% follow up,21.6% experienced immunological 
failure. Those patients are more likely to be males, illiterate with a history of 
pulmonary TB while on ART. Sub-optimal CD4 testing among PLHIV was 
associated with history of TB prior to initiation of ART and stage 3& 4 of HIV 
diseases at enrollment (8).  
Cochrane review in low resource settings, it appears that monitoring strategies 
which uses immunologic monitoring in addition to clinical monitoring for guiding 
when to switch therapy results in fewer patient deaths, fewer AIDS-defining 
illness, and fewer unnecessary switches(6).  
In twenty four studies of systematic review, studies found that reduced risk of 
mortality, progression to AIDs or death and diagnosing non-AIDs defining illness 
and an increased risk of grade three or four laboratory abnormality in patients 
initiating ART at least 350 cells/mul which supports WHO 2013 guideline 
recommendation (9). 
1.2.2 Socio-demographic characteristics  
Study in South Africa show that individuals experiencing treatment failure from 
individuals experiencing success with regard to male sex, age above 40 years(10, 
11). 
A study in northern parts of Ethiopia immunological failure was 1.78 times more 
likely among older age groups than younger one as well patient who have attained 
tertiary level education were 3.51 times more likely to experience immunological 
failure when compared with those who have never attend formal education (12).  
Study conducted at Addis Ababa public health hospitals on 103 cases and 206 
controls show that majorities, 53.4% of cases and 59.7% of controls were females. 
Regarding to marital status 42.7% of cases and 80% of controls were married(5).   
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1.2.3 Baseline information 
A retrospective cohort study in India show that suboptimal CD4 testing among 
PLHIV at stage III and IV of HIV diseases at enrollment were significantly associated 
with immunological treatment failure(13).  
A case control study in African people show that a large HIV treatment program in 
western Kenya with low baseline CD4 count <50/ml was independent predictors of 
first line treatment failure but baseline hemoglobin level, and HIV disclosure status 
were not significantly associated with risk of treatment failure(14). 
Predictor of mortality after failure of firs line  ART were weight in the lowest quartile 
for sex, CD4 T cell count ≤100, adherence <90% at the time of failure and not 
switching to second line ART. Patient who failed first line ART based on  
immunological criteria and did not switched to second line therapy faced a high 
mortality than those who switched after failure(15). 
Study on immunological failure at Adama and Yergalem hospital, in ETHIOPIA was 
found that  patient with lower baseline CD4 count were  more likely to have 
immunological treatment failure and it is noticed that patient with immunological 
treatment failure have optimal rate of immune recovery in the first six months of 
treatment with HAART(12). 
A retrospective study effects of incident tuberculosis on immunological response  of 
HIV patient with HAART shows 22.2% were found to have immunological failure with 
a rate of 8.5 per 100 person years with high immunological failure rate 20.1% per 
100 person year of TB patients at the first years of life(16).   
 
 
 
 
 
 
 
 
5 
 
1.2.4. Treatment related factors 
Study in Thailand demonstrated that even in resource settings, the high rate of 
success could be expected in the cohort with good and suitable drug adherence. 
Poor adherence was the predictors for unfavorable outcome of cART. After two 
years of cART initiation the increment of median CD4 count from base line was 152 
cells/mm3 and 294 cells/mm3 among those with and without immunological failure 
respectively(11, 17).   
A case control study in Dar es Salaam, Tanzania show that history of poor 
antiretroviral therapy adherence due to exposure to drug holydays  with loss to 
follow up, history of changing care and treatment clinics and the lack of treatment 
supporter were found to be strongly associated with the occurrence of first line 
HAART immunologic failure(18, 19). 
Study made in Italy on trends of ART drug resistance over time show that resistant 
to NRTIs and NNRTIs decline from 79.1 – 40.8% and 77.8 to 53.8 % respectively 
with p<.0001 in a time period comparison 2003-2004 to 2010-2012 with the lesson of 
mutation associated with NRTIs and NNRTs treatment failure declines over time 
regardless of specific class combination and epidemiological characteristics of 
treated population(20).     
Treatment interruption, history of pulmonary TB treatment during HAART follow up 
time and history of chronic gastric problem were independently associated with first 
line antiretroviral treatment failure(5).  
Majority of patients about 65% taking antiretroviral therapy experienced at least one 
mild to severe adverse effect in the course of treatment which can affect the patients 
treatment outcome. Due to this reason ART switch was done in about 62.8% patient 
while 37.2% of patient switched two times within three years(21).  
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1.2.5 Behavioral factors  
A meta-analysis study which compared antiretroviral resistant rates in IDU, the risk 
of development of antiretroviral resistance did not differ significantly between IDU 
and non-IDU (22). 
Immunologic failure is found to be associated with HIV status 
disclosure(AOR=3.11,95% CI=1.19-9.53) and lack of disclosure of HIV status to 
family members (AOR=3.49,95% CI=1.59-8.34) (18).  
A case control study conducted in Addis Ababa, show that most of the cases 70.9% 
and 76.7% controls disclose their HIV sero-status during HAART initiation. Majority 
of cases 63.1% and 74.8% of controls were not using any of the substance. 
However 7.8% of cases and 3.4% of controls use soft and hard drinks while 21.4% 
of cases and 14.1% of controls use two or more substances during the time of 
HAART initiation(5).  
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           1.3 justification of the study 
Achieving the vision of zero new infection, zero discrimination and zero AIDS related 
deaths requires that every one needing HIV treatment so giving emphasis on the 
issue of treatment failure have a great input for those countries with a limited access 
of ARV drug supply. Even though there are different class of ARV drugs like fusion 
inhibitor, nucleoside and nucleotide reverse transcriptase inhibitor, and protease 
inhibitors we have limited access to newer, more potent antiretroviral regimens and 
monitoring technique are often limited. So maintaining maximum efficacy of the 
available ARV drugs can be considered as the best alternative to fight against 
HIV/AIDS in resource limited country like Ethiopia. 
   Antiretroviral treatment failure leads development of drug resistant virus and let the 
patient to remain in the failing regimen unless it is detected early.  
Therefore this research lead to identify basic determinant factors which result 
antiretroviral treatment failure based on WHO immunological  treatment  failure 
criteria and findings can help for ART related programs and as a baseline for  other 
researchers. 
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       Fig.1 Conceptual framework adopted from literature review 
 
Immunologic 
Failure 
 Socio-demographic 
variables 
 Age  
 Sex 
 Marital status 
 Educational 
status  
 Religion 
 Place of 
residence 
 occupation 
 
 Base line 
information 
 WHO stage  
 Functional status 
 OIS 
 CD4 count  
 
 Treatment related factors 
 Non adherent (ART) 
 ART duration 
 Base line ART regimen  
 
 Behavioral factors  
 Disclosure status 
 Addiction  
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2. General objective:- 
 To identify determinants of first line antiretroviral immunologic  treatment failure 
among adult HIV Patients at Dessie Referral Hospital  June, 2015 
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3. Methods  
3.1. Study design  
A hospital based Unmatched case control study was employed. 
            3.2. Study area and period:- 
The study was conducted at Dessie Referral Hospital ART clinic from May 22-June 
6/2015.  
The ART Clinic of Dessie Hospital starts its service on March 2005 with having 
12461 ever enrolled adult HIV patient and 9113 ever started adult HIV patients at 
present. Out of this there are 4907 adult HIV patient on first line ART, 209 on second 
line ART. In the ART clinic there are one physician, three BSc and two diploma 
nurses, eight adherence counselor and seven case managers. 
3.3 source population:- 
All adult HIV patients’ age≥15years on ART at Dessie Referral Hospital. 
   3.4: study population:-  
Adult HIV patient with first line antiretroviral immunologic treatment failure and 
without first line antiretroviral immunological treatment failure. Cases are those adult 
HIV patients on ART greater than six months of therapy with having immunological 
treatment failure according to WHO criteria or declared as treatment failure by the 
physician/informal switching team in Dessie Referral Hospital  where as controls are 
those adult HIV patients on ART greater than six months of therapy without having 
immunological treatment failure.  
Case ascertainment:-cases have been selected by reviewing ART register, 
treatment failure data base, treatment failure screening sheet and from the detail of 
the patient history so as to classify as immunologic treatment failure. 
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3.5 inclusion criteria 
Patients with HIV infection on ART with the following criteria were included:- 
  15 years of age in adult ART clinic 
 Had at least six months of follow up and two consecutive CD4 cell count after 
ART initiation. 
 WHO immunological failure criteria as cases  
3.6 exclusion criteria 
 Patients referred from other ART treatment center with incomplete base 
line information. 
 Patient with incomplete chart/ART intake form.  
3.7 Sample size and sampling technique 
Sample size was calculated using Epi Info version 7 for unmatched case control study 
design based on the assumption that treatment interruption is significant predictor of 
first  line ART treatment failure from previous case control study with 4.4% of controls 
and 35.9% of cases were exposed to treatment interruption and the level of 
significance =0.05, the power of the test(1-)=80%, the control to case ratio(r)=1,the 
proportion of exposure among controls(p1)=4.4% with the proportion of exposure 
among cases(p2)= 35.9% and AOR=5.4.The final sample size calculated by using the 
above assumption gives 57 cases and 113 controls with a total of 170 study subjects. 
However, since there are 209 actual cases and I have about 20 independent variables, 
it was found preferable to take all the total cases in 1:1 ratio to have a total of 418 
study subjects.    
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Fig-2: Schematic presentation of sampling technique. 
Adult HIV Patient on ART at Desie Referal Hospital 
IMMUNOLOGICALTREATMENT FIALURE 
YES NO 
All cases were 
sampled=209 
Controls were 
selected with 
SRS=209  
TOTAL =418 
13 
 
3.8 Variables of the study 
3.8.1 Dependent variable:-Immunologic treatment failure 
3.8.2 Independent variables  
 Socio-demographic variables 
 Age  
 Sex 
 Marital status 
 Educational status  
 Place of residence 
 Base line information 
 Who stage  
 Functional status 
 OIS 
 CD4 count 
 Treatment related 
 Non adherent (ART) 
 ART duration 
 Base line ART regimen  
 Behavioral factors  
 addiction 
 Disclosure status 
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3.8. Operational definition:- 
Immunologic failure: patient having immunological first line antiretroviral treatment 
failure according to WHO treatment failure criteria. 
Cases:  Adult HIV patient on antiretroviral therapy at Dessie Referral Hospital with 
first line antiretroviral treatment failure confirmed by physician/informal switching 
team. 
Controls:  Adult HIV patient on antiretroviral therapy at Dessie Hospital without first 
line antiretroviral treatment failure. 
Inconsistent adherence: Adult HIV patient who have at least one record of fair or 
poor in the course of his/her treatment. 
Consistent adherent: Adult HIV patient who have no record of fair or poor in the 
course of his/her treatment or have good adherent. 
Informal switching team: - Members of health professionals which include Medical 
Doctor/physician, ART trained nurses/Health officer; they meet only so as to 
determine treatment regimen change or switching for especial cases, which needs 
specialty and team discussion.  
Switching team: Members of health professionals which include Medical 
Doctor/physician, ART trained nurses/Health officer; they meet regularly so as to 
determine treatment regimen change or switching for each and every case, which 
needs specialty and team discussion. 
Adult HIV patient: A patient with HIV on Anti-Retro viral Treatment of age > 15 
years. 
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3.9. Data collection procedure:- 
Detailed reviews of patient record was made so as to identify cases and controls 
then by using structured check list all required information was collected. Study units 
were selected independently from cases and controls. All cases with immunological 
treatment failure having complete records were taken as a whole where as controls 
were selected with simple random sampling method after creating a sampling frame 
for control group then so as to know the interval of sample selection the total 
population of the group were taken from the frame then divided by the total sample 
size then to start with the first study subject simple random sampling technique was 
applied. 
3.10 Data quality control  
To keep the quality of the study, data extraction format was prepared based on 
federal ministry of health of Ethiopia standard ART guideline, ART follow up form 
and ART intake form, the format have been tested before actual data collection have 
been conducted, Data collectors and supervisors were ART trained. Moreover, data 
quality was also assured during collection, entry and analysis. Training was given for 
data collectors and supervisors before data collection and there were close follow up 
of data collectors by supervisors and PI including observation of how they collect the 
recorded data. 
3.11 Data processing and analysis: 
Data have been first checked manually for completeness and consistency by 
supervisors and principal investigators during data collection and rechecked again 
before data entry. Normality assumption was performed before any statistical soft 
ware has been used. Data was entered and cleaned using Epi Info version 7 then 
exported to SPSS version 20 for analysis and interpretation. Descriptive analysis 
was conducted to summarize the data. Bivariable analysis has been executed to see 
the association between independent and outcome variables. All explanatory 
variables associated with outcome variables with p<0.2 was entered into 
16 
 
Multivariable logistic regression analysis. Multicolliniarity test was done to check 
whether there are correlated independent variables.   
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 4. Ethical consideration:- 
 Ethical clearance was obtained from Institutional Review Board of University of 
Gondar, School of medicine and health science. Formal letter of cooperation was 
written for Dessie Referral Hospital. Informed written Consent from Dessie Referral 
Hospital was obtained and permission letter has been written to the unit of ART 
clinic. The data collectors collect the data after obtaining permission from the unit 
department. Information and confidentiality has been maintained by enrolling data 
collectors who work at ART clinic.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18 
 
5. Results: 
5.1 characteristics of study subjects 
5.1.1 Socio demographic characteristics 
A total of 209 cases 209 controls have been included in the study. From these study 
subjects majority of them, 235(56.2 %) were females out of whom 102(48.8%) were 
cases and 133(63.6%) were controls while majority cases, 107(51.2%) were males. 
The mean age of the study participant was 35 (+ 9.2 std) years from whom majority 
of cases 93(44.5%) were in the age category of 25-34years (table 1). 
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Table I: socio demographic characteristics of adult HIV patient on ART at Dessie 
Referral Hospital, South Wollo Zone 2015. 
Socio demographic 
characteristics 
Immunological failure 
case control 
Number (%) Number (%) 
  Age  15-24 11(5.3%) 23(11.0%) 
25-34 93(44.5%) 81(38.8%) 
35-44 77(36.8%) 71(34.0%) 
>=45 28(13.4%) 34(16.3%) 
 
sex male 107(51.2%) 76(36.4%) 
female 102(48.8%) 133(63.6%) 
 
Marital status  married 102(48.8%) 106(50.7%) 
 
never married 32(15.3%)       37(17.7%) 
separated 16(7.7%) 10(4.8%) 
divorced 32(15.3%) 30(14.4%) 
widowed 27(12.9%) 26(12.4%) 
 
Level of 
education 
no education 44(21.1%) 45(21.5%) 
primary 57(27.3%) 63(30.1%) 
secondary 77(36.8%) 79(37.8%0 
tertiary 31(14.8%) 22(10.5%) 
 
Residence urban 155(74.2%) 159(76.1%) 
rural 54(25.8%) 50(23.9%) 
 
Religion  orthodox 106(50.7%) 100(47.8%) 
Muslim 97(46.4%) 104(49.8%) 
other 6(2.9%) 5(2.4%) 
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Others-protestant, catholic 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Occupation  
employed 43(20.6%) 44(21.1%) 
not employed 117(56.0%) 80(38.3%) 
farmer 11(5.3%) 10(4.8%) 
Marchant 17(8.1%) 19(9.1%) 
daily laborer 21(10.0%) 28(13.4%) 
others  28(13.4%) 
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5.1.2 Base line clinical characteristics of study subjects 
Out of 418 study population 203(48.4%) were on WHO stage III from whom 
121(57.9%) and 82(39.2%) were cases and controls respectively. 
Relatively oral candidiasis, pulmonary tuberculosis and bacterial pneumonia were 
common opportunistic infection observed in both cases and controls with relative 
higher occurrence among cases than controls (table 2). 
Table 2: Base line clinical characteristics of adult HIV patient on ART at Dessie 
Referral Hospital, South Wollo Zone 2015. 
 
        Base line clinical characteristics 
 Immunological failure 
case control 
Number (%) Number (%) 
Base line 
opportunistic 
infection 
 
 
 
Base line functional  
status 
no 
 
42(20.1%) 
 
104(49.8%) 
yes 167(79.9%) 105(50.2%) 
 
 
working 
 
 
62(29.7%) 
 
 
121(57.9%) 
ambulatory 137(65.6%) 83(39.7%) 
bed redden 
 
10(4.8%) 5(2.4%) 
base line WHO 
stage 
stage I 14(6.7%) 62(29.7%) 
stage II 39(18.7%) 48(23.0%) 
Stage III 121(57.9%) 82(39.2%) 
stage IV 35(16.7%) 17(8.1%) 
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5.1.3 Base line laboratory characteristics of study subjects 
The median base line CD4 count of study subject were 111.5 while the median CD4 
count of cases and controls were 104 and 120 respectively (figure 1). 
 
Figure I: Base line laboratory characteristics of adult HIV patient on ART at Dessie 
Referral Hospital, North Wollo Zone 2015 
5.1.4 Treatment related characteristics 
Relatively majority of study participants 109(26.1%) and 106(25.4%) were on d4T + 3TC+ 
NVP and ZDV + 3TC + NVP treatment regimen respectively, in which most of the cases 
66(31.6%) were on d4T + 3TC+ NVP. 
The mean ART duration of study subjects were 79.6(+ 25.8) where as the mean ART 
duration of cases and controls were 82(+ 24 STD) and 77(+ 25 STD) respectively. 
Three hundred sixty four (87%) of the study participant were found to be consistently 
adherent to their ART drug from whom the majority of them 203(97.1%) were controls 
 (table 3).  
126 
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Table 3: Treatment related characteristics of adult HIV patient on ART at Dessie 
Referral Hospital, south Wollo Zone 2015. 
treatment related characteristics Immunological failure 
Cases controls 
Number (%) Number (%) 
   
 Base line ART 
regimen 
1a=d4T+3TC+NVP 66(31.6%) 43(20.6%) 
1b=d4T+3TC+EFV 36(17.2%) 31(14.8%) 
1c=ZDV+3TC+NVP 52(24.9%) 54(25.8%) 
1d=ZDV+3TC+EFV 31(14.8%) 53(25.4%) 
1e=TDF+3TC+EFV 13(6.2%) 23(11.0%) 
TDF+3TC+NVP 11(5.3%) 5(2.4%) 
 
 Consistence of 
adherence 
consistent 
adherence 
161(77.0%) 203 (97.1%) 
inconsistent 
adherence 
48(23.0%) 6(2.9%) 
  duration of ART <=24 7(3.3%) 4(1.9%) 
25-48 21(10.0%) 29(13.9%) 
>=49 181(86.6%) 176(84.2%) 
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5.1.5: Behavioral characteristics 
From 209 cases and 209 controls only 59(14.1%) do not disclose their HIV status 
from whom majorities 42(20.1%) were cases with 17(8.1%) were controls (table 4). 
Table 4:  Behavioral characteristics of adult HIV patient on ART at Dessie Referral 
Hospital, south Wollo Zone 2015. 
 
behavioral characteristics 
 immunological failure 
case control 
Number(% ) Number (%) 
disclosure 
status 
Yes 167(79.9%) 192(91.9%) 
No 42(20.1%) 17(8.1%) 
 
addiction  no addiction 147(70.3%) 180(86.1%) 
Alcohol 29(13.9%) 13(6.2%) 
soft drug 27(12.9%) 14(6.7%) 
hard drugs 6(2.9%) 2(1.0%) 
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5.2. Bivariable analysis 
5.2.1 Factors which fulfill the screening criteria in bivariable analysis at p-
value < 0.2 
being female, Study population with age category 25-34 ,opportunistic infections 
WHO stage II, III and IV ,Study participants with ambulatory and bed redden 
condition, base line CD4 count <50 and CD4 count from 50-200,  
Study participants with treatment regimen d4T+3TC+EFV, ZDV+3TC+NVP,  
And ZDV+3TC+EFV, Study participants with inconsistent adherence and without 
disclosure status, Study participants with alcohol and soft drugs (table 5). 
5.3. Multivariable analysis. 
In multivariable analysis patients with base line CD4 count <50 and between 50-200 
cells/micro-litter, presence of opportunistic infection and inconsistent adherence 
were more likely to have immunologic failure whereas being female and base line 
regimen ZDV+3TC+EFV were protective (table 5). 
5.3.1 Multivariable analysis of socio demographic characteristics 
From socio demographic characteristics being female were 55% less likely to 
develop immunologic failure than being male [AOR=0.45, 95%CI: 0.25-0.80] (table 5). 
5.3.2 Multivariable analysis of clinical and laboratory base line characteristics 
Study participants with baseline CD4 count of <50 cells/micro-litter [AOR=8.04, 
95%CI: 3.53-18.3] and 50-200 cells/micro-litter [AOR=2.52, 95%CI: 1.24-5.12] were 
8.04 and 2.52 time more likely to develop immunologic failure respectively than 
those study participants with a CD4 count of >200 cells/micro-litter. 
Study subject with opportunistic infection [AOR=3.3, 95%CI: 1.76, 6.17] were found 
to have more chance of developing immunological failure than none (table 5). 
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5.3.3 Multivariable analysis of treatment related characteristics 
Study participants with treatment regimen ZDV+3TC+EFV were 65.8% less likely to 
develop immunologic failure than study participants with treatment regimen 
d4T+3TC+NVP [AOR=0.34, 95%CI: 0.16, 0.75]. 
Study participants with inconsistent adherence were 9.26 times more likely to 
develop immunological failure than who were consistently adherence [AOR=9.26, 
95%CI: 3.14, 27.31] (table 5). 
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Table 5. Bivariable and Multivariable analysis of determinant factors associated with immunologic 
failure among adult HIV patients in Dessie Referral Hospital North Wollo zone, Ethiopia, June 23, 
2015. 
 
Variables 
Immunologic failure Crude OR 
(95%CI) 
Adjusted OR 
(95%CI) 
Cases controls 
 
AGE 
 
15-24 11(5.3%) 23(11.0%) 1  
25-34 93(44.5%) 81(38.8%) 2.401(1.103, 5.226)*  
35-44 77(36.8%) 71(34.0%) 2.268(1.032, 4.984)*  
>=45 28(13.4%) 34(16.3%)   
Sex 
male 107(51.2%) 76(36.4%) 1  
female 102(48.8%) 133(63.6%) .545(.368, .805)* .451(.252, .806)* 
 
occupation 
employed 43(20.6%) 44(21.1%) 1  
not employed 117(56.0%) 80(38.3%) 1.497(.901, 2.486)  
farmer 11(5.3%) 10(4.8%)   
Marchant 17(8.1%) 19(9.1%)   
daily laborer 21(10.0%) 28(13.4%)   
others 0(0.0%) 28(13.4%) 
 
  
Base line 
WHO stage 
stage I 14(6.7%) 62(29.7%) 1  
stage II 39(18.7%) 48(23.0%) 3.598(1.756, 7.374) **  
Stage III 121(57.9%) 82(39.2%) 6.535(3.431, 12.445)**  
stage IV 35(16.7%) 17(8.1%) 
 
9.118(  4.017,20.697)**  
Base line 
functional 
status 
 
 
 
Base line 
Opportunist
ic  infection 
working 62(29.7%) 121(57.9%) 
1  
ambulatory 137(65.6%) 83(39.7%) 3.221(2.138, 4.854)**  
bed redden 10(4.8%) 5(2.4%) 3.903(1.278, 11.919)*  
no 
 
42(20.1%) 
 
104(49.8%) 
 
1 
 
yes 
167(79.9%) 105(50.2%) 3.94(2.55,6.08) 3.3(1.76,6.17) 
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Base line CD4 count <50 74(35.4%) 33(15.8%) 6.95(3.63, 13.314) ** 8.04(3.53, 18.3)** 
 
50-200 115(55.0%) 114(54.5%) 3.127(1.774, 5.511) ** 2.52(1.24, 5.117)* 
>200 20(9.6%) 62(29.7%)    1  
adherence to ART consistent adherence 161(77.0%) 203(97.1%) 
   1  
Inconsistent adherence 48(23.0%) 6(2.9%) 10.09(4.21, 24.162)** 9.26(3.14, 27.31) 
 
Base line ART 
regimen 
1a=d4T+3TC+NVP 66(31.6%) 43(20.6%) 
    1  
1b=d4T+3TC+EFV 36(17.2%) 31(14.8%) 
  
1c=ZDV+3TC+NVP 52(24.9%) 54(25.8%) .627(.365, 1.078)*  
1d=ZDV+3TC+EFV 31(14.8%) 53(25.4%) .381(.212, .685)* 
 
.342(.156, .749)* 
 
1e=TDF+3TC+EFV 13(6.2%) 23(11.0%) .368(.169, 804)* . 
TDF+3TC+NVP 11(5.3%) 5(2.4%)   
disclosure status yes 167(79.9%) 192(91.9%) 
    1  
no 42(20.1%) 17(8.1%) 2.840(1.56, 5.18)** 
 
 
addiction  no addiction 147(70.3%) 180(86.1%) 
    1  
alcohol 29(13.9%) 13(6.2%) 2.73(1.37, 5.443)*  
soft drug 27(12.9%) 14(6.7%) 2.36(1.195, 4.667)*  
Hard drugs 6(2.9%) 2(1.0%)   
*p-value       and **p-value       
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              6. Discussion 
The study focuses on the determinant factors of first line antiretroviral treatment 
immunologic failure, one of WHO treatment failure criteria especially in resource 
limited settings. In this study base line CD4 count <50 and between 50-200 
cells/micro-litter, opportunistic infection and inconsistent adherence were more likely 
to have immunologic failure whereas being female and base line regimen 
ZDV+3TC+EFV were protective. 
In socio demographic characteristics the odds of developing immunologic failure in 
females were 55% less likely than males which are inconsistent with the study 
conducted in South Africa which shows treatment success in males than females the 
possible explanation might be due to especial focus of maternal care in relation to 
HIV and ART which in turn increases adherence. 
In this study, Study participants with baseline CD4 count of <50 cells/micro-litter  
shows the odds of developing immunologic failure 8.04 times higher than  those 
study participants with base line CD4 count >200 cells/micro-litter  where as the 
odds of developing immunologic failure  in study participants with base line CD4 
ranging from 51-200 cells/micro-litter were 2. 52 times higher than those study 
participants with base line CD4 count >200 cells/micro-litter. This result is in line with  
studies conducted  in  Addis Ababa  public health  hospitals which shows Patients 
with base line CD4 count below 50cell/μl failed 2.7 times than that of with >150 
cell/μl with 95% CI 1.24 to 5.64(5), studies conducted at  Debremarkos Hospital 
which shows Patients with baseline CD4 count of less or equal to 100 cells/mm3 
were 2.16 times more likely to have immunological failure compared to those 
patients with CD4 count greater than 100 cells/mm3(23, 24). This might be due to 
the direct and indirect effect of HIV in the immune system which results challenge of 
the immunity to boost CD4 cell counts. 
Study population with opportunistic were found to have 3.3 times more chance  of 
developing  immunological failure than without opportunistic infection . This finding is 
in line with study conducted in  Addis Abeba, Hawassa and  Debremarkos  hospital 
,Ethiopia in which  Patients having history of pulmonary TB treatment during HAART 
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follow up failed almost 3 times than that of without history with 95% CI 1.55 to 5.34, 
The probability of developing new opportunistic infections like tuberculosis is high if 
the baseline CD4 count is low and Patients having recurrent pneumonia infection at 
the initiation of HAART were 1.62 times at higher risk of immunological failure 
compared to those patients without recurrent pneumonia(5, 12, 23). This may be 
due to the immunochompromizing effect of opportunistic infection and HIV in the 
immune system. 
Study participants with inconsistent adherence were 9.26 times more likely to 
develop immunological failure than who was consistently adherence this finding 
were in line with study conducted in African patients which shows poor ART 
adherence  were independent predictors of first-line treatment failure this is due to 
low level of plasma drug level creates a good opportunity to create viral resistant 
strain which in turn results treatment failure (19). 
Study participants with treatment regimen ZDV+3TC+EFV were 66% less likely to 
develop immunologic failure than study participants with treatment regimen 
d4T+3TC+NVP. This finding were inconsistent with studies conducted in African 
people, western Kenya which shows Zidovudine use as part of the NRTI backbone 
is associated with treatment failure this difference may be due to difference in first 
line regimen and parameters to change ART regimen due to side effects.  
The limitation of the study was as it is conducted  by reviewing patient records there 
are variables which can not addressed  and the study was focused  only in  
immunological failure of first line  ART drugs. 
 
 
                
, 
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    7. Limitation of the study  
 As it is conducted by reviewing patient records there are variables which 
could not be addressed.  
 The study was focused only in immunological treatment failure of first line 
ART drugs.  
 8. Conclusion  
 Low base line CD4 count <50 and between 50-200 cells/micro-litter, opportunistic 
infections and inconsistent adherence were mere likely associated  determinant 
factors for immunologic failure whereas being female and base line regimen 
ZDV+3TC+EFV were protective factors. Therefore clinicians and Anti-Retroviral 
treatment related programs shall give emphasis so as to manage such risk factors. 
 9.  Recommendation 
9.1 For health professionals  
Physicians/clinicians, Anti-Retroviral Treatment trained nurses and health officers, 
adherence counselors need to work collaborately so as to manage such risk factors. 
9.2 For Dessie referral Hospital  
Better to establish Anti-Retroviral treatment switching team from the concerned 
medical staff. 
9.3 For Ministry Of Health and Regional Health Bureau 
Better to design and strength those programs which allows establishment of Anti-
Retroviral Treatment switching team and adherence strengthening.  
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11. Annexes 
11.1 Data extraction format/check list 
This data extraction format is prepared for the collection of socio-demographic, 
clinical, treatment and immunologic information that are important for the 
assessment of immunological failure and associated factors. All this information will 
be retrieved from the patients ART intake form, follow up sheet and patient card 
without mentioning the names of the patient. This information will be collected by the 
nurse/health officer who is working in the ART clinic of Desie Hospital.  
Mr./Sr………………………………………………………………………..(Nurse/Health 
officer)  is/are requested to extract the existing data as you are participating in this 
research project. 
Part I:- socio-demographic variables 
Circle the corresponding number of response and say incomplete (IC) when the data 
was not documented.  
no variables Response with corresponding 
no/code 
Remark/skip 
to 
101 Age , at enrollment in 
years 
 
…………………… 
 
102  sex 1. Male        2. female  
103 Marital status 1. never married 
2. Married 
3. Separated 
4. Divorced 
5. Widowed 
6. IC 
 
104 Levels of education 1. No education 
2. Primary 
3. Secondary 
4. Tertiary 
5. IC  
 
105 Residence 1. Urban 
2. rural 
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106 religion 1. orthodox 
2. Muslim 
3. catholic 
4. protestant 
5. others (spacify)……………………… 
 
 
107 occupation 1. Not  employed 
2. Employed 
3. Farmer 
4. Marchant /retialor 
5. Daily laborer/migrant worker 
6. Others (specify)………………………. 
 
 
 
Part II:-Base line information/at the time of enrollment, date of enrollment…………………………….EFY 
201 Base line CD4 count List ………………………………….  
202 Opportunistic 
infection  
List………………………………….  
203 Functional status at 
the time of 
enrollment  
1. Working  
2. Ambulatory 
3. Bedridden 
 
 
204 WHO stage 1. Stage I 
2. Stage II 
3. Stage III 
4. Stage IV 
 
 
205 Body weight 
 
……………….Kg 
 
 
206  laboratory 
information 
Hg…………………….Mg/dl 
Hct……………………..% 
WBC……………………../mm3 
 
 
 
 
Part  Iv:-Antiretroviral treatment related variables 
401 Duration of  HIV test 
in month 
 
…………………………………………….. 
ART  
INTAKE/FOLLOW 
UP FORM 
402 Time of eligibility for 
ART in month 
Total month…………………………………. 
Date of start…………………………….. 
 
 
403 Eligibility criteria for 
ART at enrolment 
1. Immunological /CD4………………. 
2. Who stage……………….. 
3. Both 
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4. Virological failure 
5. all 
404 Initial regimen of 
ART at enrollment 
1. 1a=d4T+3TC+NVP 
2. 1b=d4T+3TC+EFV 
3. 1c=ZDV+3TC+NVP 
4. 1d= ZDV+3TC+EFV 
5. 1e=TDF+3TC+EFV 
6. TDF+3TC+NVP  
7. 2a=ABC+ ddI + LPV/r 
8. 2b=TDF +3TC + LPV/r 
9. 2c=ZDV+3TC+ LPV/r 
10. 2d= ZDV+ABC+LPV/r 
11. Others (specify)………………… 
………………………………….   
 
405 Duration  on ART Total MONTH………………………. 
Date of start………………………… 
 
 
406 
 
Exposure history of 
ARV drugs before 
starting first line ART 
 
1. YES 
2. NO 
 
 
if “no” skip to 208 
Otherwise go to 
207 
407 Which ARV/ART 
drug/regimen 
List the regimen/drug……………………. 
………………………………………………. 
 
408 Enrolled to CPT in 
the last six month 
1. Yes 
2. No 
 
 
409 Adherence to ART in 
the last 6 month 
1. G-good 
2. F-fair 
3. P- poor 
 
 
410 Any change or 
switch of ARV 
Regimen OR 
individual drug 
1. Yes 
2. no 
If no skip to 
…..other wise go to 
211 
 
411 
 
 
Switching time after 
original treatment 
 
Total month………………….. 
 Date of switching………………………… 
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412 
 
 
Write the current 
ART regimen or in 
the previous six 
months 
 
 
1. 1a=d4T+3TC+NVP 
2. 1b=d4T+3TC+EFV 
3. 1c=ZDV+3TC+NVP 
4. 1d= ZDV+3TC+EFV 
5. 1e=TDF+3TC+EFV 
6. TDF+3TC+NVP 
 second line ART  
1. 2a=ABC+ ddI + LPV/r 
2. 2b=TDF +3TC + LPV/r 
3. 2c=ZDV+3TC+ LPV/r 
4. 2d= ZDV+ABC+LPV/r 
5. Others (specify)………………… 
………………………………….   
 
413 Reason  for change  
or switch of ARV 
regimen or 
individual drug 
1. Toxicity of drug 
2. Pregnancy 
3. TB-co treatment  
4. Drug stock out 
5. Treatment failure 
6. Others (specify)………………… 
……………………………………. 
 
 
Part V:-behavioral factors 
501 Disclosure status 1. Yes 
2. no 
 
502 addiction 1. tobacco 
2. alcohol 
3. soft drugs 
4. hard drugs 
5. IC 
 
503    
 
 
 
 
 
 
 
 
39 
 
 
11.2 Information sheet and consent form 
Title of the research project 
Determinants of first line antiretroviral immunologic treatment failure among adult 
HIV Patients at Dessie referral hospital, May, 2015: A case control study. 
Name of principal investigator________________Abinet Dagnaw 
Name of the Organization____________________ University of Gondar, school of 
medicine. 
Name of sponsor ________________________Amhara regional health bureau  
Information sheet and consent form were prepared for database and patient card 
unit workers at Dessie referral hospital for this research project which assess 
determinant factors of immunologic failure of first line antiretroviral treatment failure. 
Introduction  
This information and consent form were prepared with the aim of explaining the 
research project that joins a research investigator. The main aim of the research 
project was to assess determinant factors of immunologic failure of first line 
antiretroviral treatment failure at Dessie referral hospital. 
Purpose of the research project 
The aim of this study was to examine determinant factors related to immunologic 
failure of first line antiretroviral treatment failure at Dessie referral hospital. 
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